| Stehlik, Josef |
NCT05420012: The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation |
|
|
| Completed | 4 | 26 | US | Vericiguat, VERQUVO, Placebo, Control group | Josef Stehlik, Merck Sharp & Dohme LLC | Heart Failure, Heart Failure with Reduced Ejection Fraction (HFrEF) | 10/24 | 10/24 | | |
NCT06625073: Randomized Trial of SGLT2i in Heart Transplant Recipients |
|
|
| Not yet recruiting | 4 | 200 | US | Empagliflozin, Jardiance, Placebo, Control Group | VA Office of Research and Development | Heart Transplant, Cardiovascular Disease, Kidney Disease | 08/29 | 02/30 | | |
| Active, not recruiting | 2 | 385 | US | tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone | National Institute of Allergy and Infectious Diseases (NIAID), PPD | Heart Transplant | 04/25 | 04/25 | | |
| Withdrawn | N/A | 600 | NA | Prospera Transplant Assessment, Endomyocardial biopsy | Natera, Inc. | Heart Transplant Failure and Rejection | 01/25 | 01/26 | | |
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy |
|
|
| Recruiting | N/A | 250 | US | The Prospera™ Test | Natera, Inc. | Heart Transplant Failure and Rejection | 12/24 | 12/25 | | |
| Completed | N/A | 208 | US | Remote monitoring and predictive analytics, Sham comparator | VA Office of Research and Development, George E. Wahlen Department of Veterans Affairs Medical Center, Michael E. DeBakey VA Medical Center, VA Palo Alto Health Care System, Malcom Randall VA Medical Center, Hunter Holmes McGuire VA Medical Center, VHA Innovation Ecosystem | Heart Failure | 08/24 | 10/24 | | |
NCT02670408: Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation |
|
|
| Recruiting | N/A | 900 | Europe, Canada, US, RoW | Endomyocardial biopsy | University of Alberta | Cardiac Transplant Disorder | 12/25 | 07/26 | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx diagnostic test, Prospera, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Heart Transplant Rejection | 12/26 | 07/27 | | |
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation |
|
|
| Completed | N/A | 147 | US | Prospera | Natera, Inc. | Heart Transplant | 10/24 | 10/24 | | |
IICAPTAIN-HF, NCT06526988: Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure |
|
|
| Not yet recruiting | N/A | 2200 | US | EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert | University of Colorado, Denver, Patient-Centered Outcomes Research Institute, Yale University, Northwestern University, University of Utah, Sutter Health | Heart Failure With Reduced Ejection Fraction | 09/28 | 09/28 | | |
NCT01099982: Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease |
|
|
| Recruiting | N/A | 300 | US | | University of Utah, Intermountain Health Care, Inc., VA Salt Lake City Health Care System, Hunter Holmes McGuire VA Medical Center | Congestive Heart Failure | 01/28 | 01/28 | | |
| Marchand, William |
NCT03677882: A Brief Mind-Body Bridging Intervention for Suicidal Ideation |
|
|
| Terminated | N/A | 13 | US | Mind Body Bridging Group Session | VA Salt Lake City Health Care System, Mind Body Bridging Charity | Suicidal Ideation, Mind Body Bridging | 01/23 | 01/23 | | |
| Completed | N/A | 25 | US | Brief Mindfulness Based Intervention, MB-SI+ TAU | VA Salt Lake City Health Care System | Suicidal Ideation, Psychiatric Disorder, Addiction | 01/23 | 01/23 | | |
NCT06300255: Evaluation of the H.O.O.V.E.S. Healing Intensives Program |
|
|
| Recruiting | N/A | 250 | US | H.O.O.V.E.S. Healing Intensives | VA Salt Lake City Health Care System | Anxiety, PTSD, Depression | 02/29 | 02/29 | | |
| Active, not recruiting | N/A | 200 | US | Equine Therapy, Therapeutic Horsemanship Program | VA Salt Lake City Health Care System, Utah State University | PTSD | 12/24 | 12/24 | | |
| Drakos, Stavros |
| Recruiting | N/A | 100 | US | Controlled Cardiac Reloading through LVAD Speed Adjustment | STAVROS G DRAKOS, American Heart Association | Heart Failure | 06/26 | 06/28 | | |
NCT04977310: TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading Vs. Standard of Care |
|
|
| Withdrawn | N/A | 10 | US | CardioMEMS | STAVROS G DRAKOS, Abbott | Heart Failure | 09/26 | 09/26 | | |
| Recruiting | N/A | 500 | Canada, US | | STAVROS G DRAKOS | Cardiogenic Shock, Acute Myocardial Infarction | 12/27 | 12/27 | | |
NCT01099982: Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease |
|
|
| Recruiting | N/A | 300 | US | | University of Utah, Intermountain Health Care, Inc., VA Salt Lake City Health Care System, Hunter Holmes McGuire VA Medical Center | Congestive Heart Failure | 01/28 | 01/28 | | |
| Godfrey, Bradeigh |
NCT05367271: The Efficacy of Botulinum Toxin Vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis |
|
|
| Completed | 2/3 | 62 | US | Botulinum Toxin A, OnabotulinumtoxinA, BTX-A, Dexamethasone, Cortisone | Western Institute for Veterans Research | Plantar Fasciitis | 09/24 | 09/24 | | |
| Rhoads, Jamie |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
NCT05625633: Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts |
|
|
| Recruiting | 2/3 | 120 | US | Human Papillomavirus 9-valent Vaccine, Recombinant, Gardasil 9, 9-valent Gardasil, Normal Saline | Western Institute for Veterans Research, University of Utah, Merck Sharp & Dohme LLC | Warts | 12/25 | 12/26 | | |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Klein, Stephanie Z |
NCT05625633: Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts |
|
|
| Recruiting | 2/3 | 120 | US | Human Papillomavirus 9-valent Vaccine, Recombinant, Gardasil 9, 9-valent Gardasil, Normal Saline | Western Institute for Veterans Research, University of Utah, Merck Sharp & Dohme LLC | Warts | 12/25 | 12/26 | | |
NCT04924036: Qbrexza Cloths for Hyperhidrosis of Amputation Sites |
|
|
| Completed | 2 | 14 | US | glycopyrronium cloths, Qbrexza Cloths, Placebo | University of Utah | Amputation, Hyperhidrosis | 12/23 | 12/23 | | |
| Roberge, Erika |
NCT05422768: PTSD Clinical Team Research Clinic (PCT Research Clinic) |
|
|
| Active, not recruiting | N/A | 118 | US | Warrior Renew, Warrior Renew + EAL | VA Salt Lake City Health Care System | PTSD | 05/24 | 05/24 | | |
| Recruiting | N/A | 270 | US | Modified A-B-C: Working with Events, Thoughts, and Feelings, Challenging Questions, Patterns of Problematic Thinking, Challenging Beliefs, Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy) | VA Office of Research and Development | Stress Disorders, Post-Traumatic | 07/25 | 03/26 | | |
| Anderson, Mikol |
NCT05367271: The Efficacy of Botulinum Toxin Vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis |
|
|
| Completed | 2/3 | 62 | US | Botulinum Toxin A, OnabotulinumtoxinA, BTX-A, Dexamethasone, Cortisone | Western Institute for Veterans Research | Plantar Fasciitis | 09/24 | 09/24 | | |
| Nicholson, Lowell |
NCT05625633: Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts |
|
|
| Recruiting | 2/3 | 120 | US | Human Papillomavirus 9-valent Vaccine, Recombinant, Gardasil 9, 9-valent Gardasil, Normal Saline | Western Institute for Veterans Research, University of Utah, Merck Sharp & Dohme LLC | Warts | 12/25 | 12/26 | | |
